Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-468-6 | CAS number: 107-15-3
Endpoint summary
Administrative data
Description of key information
In repeated dose studies, decreased body weights and water and feed consumption have been observed, and are probably related to the irritating nature of EDA and its high pH. Hepatocellular pleomorphism has been observed and also increased ASAT and ALAS values.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 22 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Well reported good quality study Klimisch 2.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEC
- 327 mg/m³
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- Somewhat limited study of 6 week duration, full details are not available in the publication.
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 8.3 mg/kg bw/day
- Study duration:
- chronic
- Species:
- mouse
- Quality of whole database:
- Study limited by single dose level but did include positive control. Study was aimed at comparing two samples of ethylene diamine with different impurity profiles. The study demonstrated no adverse effects at highest none irritant dose.
Additional information
There are three oral repeat dose studies, the key study being a reasonable modern 90 day dietary study, with Ethylenediamine dihydrochloride. A NOAEL was determined at 22 mg/kg/day after adjustment to the dose level as Ethylenediamine base. There is also a 2 year cancer bioassay which had a NOAEL of 9 mg/kg/day but this NOAEL may have been quite higher as the next dose level was 45 mg/kg/day as Ethylenediamine base. The third oral study investigated specific effects on the eyes at a significantly higher dose with no NOAEL. There is a 6 -week inhalation study which established a NOAEC of 144 mg/m3 and a dermal study which had a NOAEL of at least 8.3 mg/kg bw/day (only dose tested).
Based on this the key value is the 22 mg/kg day NOAEL from the 90 day dietary study.
Justification for classification or non-classification
The classification for repeated dose toxicity for a 90-day study is based on serious adverse effects seen at dose levels of 100 mg/kg or less. In the 90 -day study the probably none reversible effect was seen at the highest dose level of 456 mg/kg/day with relatively minor effects at 114 mg/kg/day as ethylendiamine base. As the top dose at which the serious adverse effects were seen was well above the 100 mg/kg bw/day upper limit for classification of STOT (Specific Target Organ Toxicity) at Category 2, no classification for repeated dose toxicity is required under the current EU CLP and GHS criteria.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
